Finerenone reduces AF risk in patients with heart failure, diabetes, kidney disease

CHICAGO — Finerenone prevented new-onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes or heart failure with mildly reduced or preserved ejection fraction, according to new data from FINE-HEART.As Healio previously reported, in the main results of FINE-HEART, a pooled analysis of the FINEARTS-HF, FIDELIO-DKD and FIGARO-DKD trials of the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone (Kerendia, Bayer), finerenone reduced risk for death, HF hospitalization and a composite of kidney-related endpoints compared withRead More